Adherence to artemether-lumefantrine drug combination: A rural community experience six years after change of malaria treatment policy in Tanzania

Malaria Journal

Volumn 13, Issue 1, 2014, Pages

  Minzi, Omary ^a   Maige, Sylivester ^b   Sasi, Philip ^a   Ngasala, Billy ^a  

^a MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^b Medical Stores Department   (Tanzania)

Author keywords

Adherence; Artemisinin lumefantrine combination therapy; Parasite clearance

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; BENFLUMETOL; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DRUG COMBINATION; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; BLISTER PACK; BLOOD SAMPLING; CAPILLARY BLOOD; CHILD; CONTROLLED STUDY; DRUG BLOOD LEVEL; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; HEALTH CARE POLICY; HOME CARE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA; MALE; MEDICATION COMPLIANCE; MICROSCOPY; MORNING DOSAGE; NEWBORN; OBSERVATIONAL STUDY; OPEN STUDY; PARASITE; PATIENT COMPLIANCE; PROFESSIONAL PRACTICE; PROSPECTIVE STUDY; RURAL POPULATION; SELF REPORT; SINGLE DRUG DOSE; TANZANIA; VENOUS BLOOD; AGED; DRUG COMBINATION; MIDDLE AGED; PRESCHOOL CHILD; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; FLUORENES; HUMANS; INFANT; MALARIA; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROSPECTIVE STUDIES; RURAL POPULATION; TANZANIA; YOUNG ADULT;

EID: 84903872493     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-13-267     Document Type: Article

References (20)

1. WHO, Adherence to Long-Term Therapies Geneva: World Health Organization 2003
2. Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi. Bell DJ, Wootton D, Mukaka M, Montgomery J, Kayange N, Chimpeni P, Hughes DA, Molyneux ME, Ward SA, Winstanley PA, Lalloo DG, Malar J 2009 8 204
3. Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance. White NJ, Pongtavornpinyo W, Maude RJ, Saralamba S, Aguas R, Stepniewska K, Lee SJ, Dondorp AM, White LJ, Day NPJ, Malar J 2009 8 253
4. Ministry of Health and Social Welfare, United Republic of Tanzania, Tanzania National Guidelines for Diagnosis and Treatment of Malaria 2005
5. Adherence to a six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Uganda. Fogg C, Bajunirwe F, Piola P, Biraro S, Checchi F, Kiguli J, Namiiro P, Musabe J, Kyomugisha A, Guthmann J-P, Amer J Trop Med Hyg 2004 71 525 530 (Pubitemid 39601144)
6. Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda. Checchi F, Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, Ruzagira E, Babigumira J, Kigozi I, Kiguli J, Kyomuhendo J, Ferradini L, Taylor WRJ, Guthmann J-P, Malar J 2006 5 59
7. Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania. Kabanywanyi AM, Lengeler C, Kasim P, King'eng'ena S, Schlienger R, Mulure N, Genton B, Malar J 2010 9 48
8. Adherence to the combination of sulphadoxine-pyrimethamine and artesunate in the Maheba refugee settlement, Zambia. Depoortere E, Guthmann J-P, Sipilanyambe N, Nkandu E, Fermon F, Balkan S, Legros D, Trop Med Int Health 2004 9 62 67 (Pubitemid 38178013)
9. Adherence to a combination of artemether and lumefantrine (Coartem) in Kajo Keji, Southern Sudan. Depoortere E, Salvador ET, Stivanello E, Bisoffi Z, Guthmann J-P, Ann Trop Med Parasitol 2004 98 635 637 (Pubitemid 39215518)
10. High adherence to artemether-lumefantrine treatment in children under real-life situation in rural Tanzania. Simba D, Kakoko D, Tomson G, Premji P, Petzold M, Mahindi M, Gustafsson L, Trans R Soc Trop Med Hyg 2012 106 3 9
11. Adherence to prescribed artemisinin-based combination therapy in Garissa and Bunyala districts, Kenya. Lawford H, Zurovac D, O'Reilly L, Hoibak S, Cowley A, Munga S, Vuvule J, Juma E, Snow RW, Allan R, Malar J 2011 10 281
12. Adherence to a six-dose regimen of artemether-lumefantrine among uncomplicated Plasmodium falciparum patients in the Tigray Region, Ethiopia. Lemma H, Löfgren C, San Sebastian M, Malar J 2011 10 349
13. Ascertaining baseline levels of antiretroviral therapy adherence in Uganda: a multimethod approach. Kunutsor S, Evans M, Thoulass J, Walley J, Katabira E, Newell JN, Muchuro S, Balidawa H, Namagala E, Ikoona E, J Acquir Immune Defic Syndr 2010 55 221 224
14. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Price RN, Uhlemann A, Van Vugt M, Brockman A, Hutagalung R, Nair S, Nash D, Singhasivanon P, Anderson TJC, Krishna S, White NJ, Nosten F, Clin Infect Dis 2006 42 1570 1577
15. Malaria infection potential of anopheline mosquitoes sampled by light trapping indoors in coastal Tanzanian villages. Shiff CJ, Minjas JN, Hall T, Hunt RH, Lyimo SDJ, Med Vet Entomol 1995 9 256 262
16. Interlaboratory development and cross validation of a chromatographic method for determination of lumefantrine in human plasma-a proficient capacity assessment of bioanalytical laboratories in East Africa. Minzi O, Ngaimisi E, Shewiyo DH, Sasi P, Ignace A, J Anal & BioanalTechn 2012 3 3 7
17. Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. White NJ, van Vugt M, Ezzet F, Clin Pharmacokinet 1999 37 105 125
18. Preventing antimalarial drug resistance through combinations. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy. White NJ, Drug Resist Updat 1998 1 3 9
19. Clinical and pharmacokinetic trial of six doses of artemether- lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. Lefèvre G, Looareesuwan S, Treeprasertsuk S, Krudsood S, Silachamroon U, Gathmann I, Mull R, Bakshi RA, Am J Trop Med Hyg 2001 64 247 256
20. Comparison of bioavailability between the most available generic tablet formulation containing artemether and lumefantrine on the Tanzanian market and the innovator's product. Minzi OMS, Marealle IA, Shekalaghe S, Juma O, Ngaimisi E, Chemba M, Rutaihwa M, Abdulla S, Sasi P, Malar J 2013 12 174